926272-43-7

Basic information

• Product Name: 2-(2-Methyl-1-piperidinyl)-5-(trifluoromethyl)-phenylamine
• Synonyms: 2-(2-Methyl-1-piperidinyl)-5-(trifluoromethyl)-phenylamine
• CAS NO: 926272-43-7
• Molecular Formula: C13H17F3N2
• Molecular Weight: 258.2826896
• Mol File: 926272-43-7.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(2-Methyl-1-piperidinyl)-5-(trifluoromethyl)-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Methyl-1-piperidinyl)-5-(trifluoromethyl)-phenylamine(926272-43-7)
• EPA Substance Registry System: 2-(2-Methyl-1-piperidinyl)-5-(trifluoromethyl)-phenylamine(926272-43-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 926272-43-7(Hazardous Substances Data)

Usage

Structure

Substituted aniline derivative with a trifluoromethyl group attached to the phenyl ring, and piperidine and methylamino groups attached to the amino group

Classification

Tertiary amine

Biological activity

Potential to interact with neurotransmitter receptors

Applications

Medicinal chemistry, drug development, industrial and research fields

Safety

Handle with caution and follow safety protocols due to potential hazards.

Upstream product

• 1722-95-8 (2R)-methylpiperidine 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 
• 3197-42-0 (S)-2-methylpiperidine 
• 858126-24-6 (S)-2-methyl-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine 

Relevant articles and documents

COMPOUNDS

The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR13R14, optionally substituted heteroaryl and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H, C1-C3-alkyl, or halo; R10 and R11, together with the nitrogen to which they are attached, form an azepanyl group, wherein (a) said azepanyl group is substituted by one or more substituents, or (b) one or two carbons in said azepanyl group are replaced by a group selected from O, NH, S and CO, and said azepanyl group is optionally further substituted; or R10 and R11, together with the nitrogen to which they are attached, form an azetidinyl, pyrrolidinyl or piperidinyl group wherein (a) said azetidinyl, pyrrolidinyl or piperidinyl group is substituted by one or more substituents, or (b) one or two carbons in said azetidinyl, pyrrolidinyl or piperidinyl group are replaced by a group selected from NH, S and CO; or R10 and R11, together with the nitrogen to which they are attached, form an 8, 9 or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic heterocycloalkyl group is optionally substituted; or R10 and R11, together with the nitrogen to which they are attached, form a 6 to 12-membered bicyclic group containing a spirocyclic carbon atom, wherein one or two carbons in the bicyclic group are optionally replaced by a group selected from O, NH, S and CO, and said bicyclic group is optionally substituted, or said bicyclic group is optionally fused to a 5 or 6-membered aryl or heteroaryl group; R13 and R14 are each independently H or alkyl. Further aspects of the invention relate to such compounds for use in the field of immune-oncology and related applications.